Eligibility of BC patients to HER2-targeted therapy depends on detection of HER2/ERBB2 overexpression/amplification in the tumor tissue by immunohistochemistry (IHC) and/or in situ hybridization (ISH). This evidence concerns the gene ERBB2 and breast cancer.